Trial | NCT03955367  Report issue

Title

Pelvic RT Versus Prophylactic Extended-field RT in Patients With Cervical Cancer
Pelvic Irradiation Versus Prophylactic Extended-field Irradiation in Selected Patients With Cervical Cancer Treated With Concurrent Chemoradiotherapy: A Multicenter, Open-label, Randomized, Phase 3 Trial

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Recruiting

  • Study Participants

    638
To investigate the value of prophylactic extended-field irradiation (EFI), we conduct a randomized clinical trial to compare the efficacy and toxicity of pelvic irradiation and prophylactic EFI in selected patients with cervical cancer treated with definitive concurrent chemoradiotherapy. External beam radiation therapy is delivered with intensity-modulated radiation therapy (IMRT).
This is a multicenter, open-label, phase III randomized clinical trial. Cervical cancer patients without evidence of para-aortic metastatic lymph nodes (MLNs) and with at least one of the following characteristics are included in the present study: (a) Number of pelvic MLNs ≥ 2; (b)Short diameter of pelvic MLNs ≥ 1.5cm; (c)Pelvic wall involvement. Patients are randomly assigned to pelvic irradiation group and prophylactic EFI group. Patients in pelvic irradiation group receive pelvic irradiation, intracavitary brachytherapy and concurrent chemotherapy. Patients in prophylactic EFI group receive irradiation for pelvis and para-aortic lymph nodes region, intracavitary brachytherapy and concurrent chemotherapy. The upper border of clinical target volume (CTV) is at the level of renal vessels for patients in prophylactic EFI group. A dose of 45-50.4 Gy is delivered to CTV with IMRT in both groups. Patients receive cisplatin based concurrent chemotherapy (single cisplatin or cisplatin plus paclitaxel). The primary endpoint is progression-free survival.
Study Started
Jun 17
2019
Primary Completion
Jun 01
2022
Anticipated
Study Completion
Jun 01
2025
Anticipated
Last Update
Feb 23
2022

Radiation Prophylactic extended-field Irradiation

CTV covers pelvis and para-aortic lymph nodes region.

  • Other names: Prophylactic radiotherapy for para-aortic lymph nodes region

Radiation Pelvic irradiation

CTV covers pelvis.

  • Other names: Pelvic radiotherapy

Radiation Intracavitary brachytherapy

The total dose delivered to point A or high-risk CTV is ≥80Gy. For patients with larger-volume cervical tumor, the total dose is ≥85Gy.

  • Other names: Brachytherapy

Drug Concurrent chemotherapy [nedaplatin, docetaxel (taxotere)]

Cisplatin based concurrent chemotherapy, including cisplatin as a single agent or cisplatin plus Paclitaxel.

  • Other names: Chemotherapy

Pelvic Irradiation Active Comparator

Patients receive concurrent chemoradiotherapy. The CTV includes the gross tumor, cervix, uterus, parametrium, upper part of the vagina, and pelvic lymph nodes regions. The upper border of CTV is at the level of aortic bifurcation. A dose of 45-50.4Gy is delivered to CTV with IMRT.

Prophylactic EFI Experimental

Patients receive concurrent chemoradiotherapy. The CTV includes the gross tumor, cervix, uterus, parametrium, upper part of the vagina, pelvic lymph nodes regions and para-aortic lymph nodes region. The upper border of CTV is at the level of renal vessels. A dose of 45-50.4Gy is delivered to CTV with IMRT.

Criteria 

Inclusion Criteria:

Patients must be informed of the investigational nature of this study and give written informed consent with 30 days before treatment.
Age ≥18 years and ≤ 70 years.
Patients with newly histologically confirmed cervical cancer, including squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma, et al.
No evidence of para-aortic metastatic lymph nodes (MLNs) on CT, MRI or positron emission tomograph (PET)/CT.*
No evidence of distant metastasis (FIGO stage IVB).

At least meet one of the following characteristics:

Number of pelvic MLNs ≥ 2;
Short diameter of pelvic MLNs ≥ 1.5cm; *
Parametrial involvement to the pelvic wall ＃.
Satisfactory performance: Eastern Cooperative Oncology Group (ECOG) score ≥ 2.
Adequate marrow: neutrophile granulocyte count ≥1.5*10^9/L, hemoglobin ≥ 80 g/L, platelet count ≥100*10^9/L.

Normal liver and kidney function: Creatinine (Cr) < 1.5 mg/dl, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) < 2*upper limit of normal (ULN).

MLNs refer to positive lymph nodes confirmed by PET/CT or lymph nodes with short diameter ≥ 1 cm on CT or MRI.

Parametrial involvement to the pelvic wall is diagnosed with gynecological examination or MRI;

Exclusion Criteria:

With common iliac MLNs.
Tumor extended to the lower third of the vagina.
Tumor spread to mucosa of the bladder or rectum.
Prior surgery (including pelvic or para-aortic lymph nodes resection, except for tumor biopsy), radiotherapy or chemotherapy to primary tumor or nodes.
Prior malignancy.
History of previous radiotherapy to the abdomen or pelvis.
Pregnancy or lactation.
Active inflammatory bowel disease, or history of severe stomach or duodenal ulcer.
Active infection with fever.
Patients with unacceptable risk that intracavitary brachytherapy can not be conducted.
Any severe disease which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control, and emotional disturbance.
No Results Posted